Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol

Alessandro Ottaiano,Stefania Scala,Mariachiara Santorsola,Anna Maria Trotta,Crescenzo DAlterio,Luigi Portella,Ottavia Clemente,Anna Nappi,N. Zanaletti,Alfonso De Stefano,Antonio Avallone,Vincenza Granata,Carmen Notariello,Amalia Luce,Angela Lombardi,Carmine Picone,Antonella Petrillo,Francesco Perri,Fabiana Tatangelo,Annabella Di Mauro,Vittorio Albino,Francesco Izzo,Daniela Rega,Ugo Pace,Massimiliano Di Marzo,Paolo Chiodini,Gianfranco De Feo,Paola Del Prete,Gerardo Botti,Paolo Delrio,Michele Caraglia,Guglielmo Nasti

Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol

2021

Background:The intensive study of predictive factors has strongly ameliorated the therapeutic flow-chart of metastatic colorectal cancer (mCRC) by allowing the selection of patients who benefit fro...

Keywords:

Aflibercept
Bevacizumab
Colorectal cancer
Oncology
Internal medicine
MRAS
Irinotecan
Selection (genetic algorithm)
FOLFIRI
Medicine
Arbitration

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations